A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil

Cynthia S Firnhaber

Status: Completed

Conditions: HIV; HIV Infections

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00840905

Merck P0806

Details and patient eligibility

About

This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.

Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be <50% in HIV seropositive women in resource limited countries.

Full description

Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .

Enrollment: 487 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV seropositive women 18 years of age and older Consent signed per local IRB requirement

Exclusion criteria

• Can not give blood

Trial design

487 participants in 3 patient groups

1

Description:

HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa

2

Description:

A cohort of HIV seropositive women from Gabarone Botswana

3

Description:

A cohort of HIV seropositive women from Rio De Janeiro Brasil